A case of pulmonary adenocarcinoma showing rapid progression of peritoneal dissemination after immune checkpoint inhibitor therapy

Taro Shinozaki, Eri Iwami, Shinnosuke Ikemura, Tatsu Matsuzaki, Takahiro Nakajima, Kazuhiko Hashimoto, Takeshi Terashima

研究成果: Article

5 引用 (Scopus)

抄録

Background: Immune checkpoint inhibitors are standard treatments for non-small cell lung cancer. Unique cases with paradoxical acceleration of the disease after immunotherapy have been reported. These have been described as cases of hyperprogressive disease. Case presentation: A 76-year-old man was diagnosed with pulmonary adenocarcinoma with pleural dissemination and liver and adrenal metastases. Genomic analysis revealed neither EGFR mutations nor ALK translocations. Immunohistochemical analysis revealed a programmed death-ligand 1 tumor proportion score of 23%. Chemotherapy with carboplatin, paclitaxel, and bevacizumab resulted in Grade 3 skin eruption and disease progression. Pembrolizumab was initiated as a second-line treatment. However, peritoneal dissemination and ascites developed. The patient died 2weeks later. The autopsy revealed widespread peritoneal dissemination and an extensive hemorrhagic infarction. Conclusion: This was a rare case of hyperprogressive disease with rapid progression of peritoneal dissemination after pembrolizumab treatment.

元の言語English
記事番号620
ジャーナルBMC Cancer
18
発行部数1
DOI
出版物ステータスPublished - 2018 5 31
外部発表Yes

Fingerprint

Carboplatin
Paclitaxel
Skin Diseases
Ascites
Non-Small Cell Lung Carcinoma
Immunotherapy
Infarction
Disease Progression
Autopsy
Therapeutics
Neoplasm Metastasis
Ligands
Drug Therapy
Mutation
Liver
Adenocarcinoma of lung
Neoplasms
pembrolizumab
Bevacizumab

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research

これを引用

A case of pulmonary adenocarcinoma showing rapid progression of peritoneal dissemination after immune checkpoint inhibitor therapy. / Shinozaki, Taro; Iwami, Eri; Ikemura, Shinnosuke; Matsuzaki, Tatsu; Nakajima, Takahiro; Hashimoto, Kazuhiko; Terashima, Takeshi.

:: BMC Cancer, 巻 18, 番号 1, 620, 31.05.2018.

研究成果: Article

Shinozaki, Taro ; Iwami, Eri ; Ikemura, Shinnosuke ; Matsuzaki, Tatsu ; Nakajima, Takahiro ; Hashimoto, Kazuhiko ; Terashima, Takeshi. / A case of pulmonary adenocarcinoma showing rapid progression of peritoneal dissemination after immune checkpoint inhibitor therapy. :: BMC Cancer. 2018 ; 巻 18, 番号 1.
@article{0e2d58e72c8f40118b4aaa60cb96f47d,
title = "A case of pulmonary adenocarcinoma showing rapid progression of peritoneal dissemination after immune checkpoint inhibitor therapy",
abstract = "Background: Immune checkpoint inhibitors are standard treatments for non-small cell lung cancer. Unique cases with paradoxical acceleration of the disease after immunotherapy have been reported. These have been described as cases of hyperprogressive disease. Case presentation: A 76-year-old man was diagnosed with pulmonary adenocarcinoma with pleural dissemination and liver and adrenal metastases. Genomic analysis revealed neither EGFR mutations nor ALK translocations. Immunohistochemical analysis revealed a programmed death-ligand 1 tumor proportion score of 23{\%}. Chemotherapy with carboplatin, paclitaxel, and bevacizumab resulted in Grade 3 skin eruption and disease progression. Pembrolizumab was initiated as a second-line treatment. However, peritoneal dissemination and ascites developed. The patient died 2weeks later. The autopsy revealed widespread peritoneal dissemination and an extensive hemorrhagic infarction. Conclusion: This was a rare case of hyperprogressive disease with rapid progression of peritoneal dissemination after pembrolizumab treatment.",
keywords = "Adenocarcinoma, Hyperprogressive disease, Immune checkpoint inhibitor, Lung cancer, Pembrolizumab, Peritoneal dissemination",
author = "Taro Shinozaki and Eri Iwami and Shinnosuke Ikemura and Tatsu Matsuzaki and Takahiro Nakajima and Kazuhiko Hashimoto and Takeshi Terashima",
year = "2018",
month = "5",
day = "31",
doi = "10.1186/s12885-018-4549-5",
language = "English",
volume = "18",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - A case of pulmonary adenocarcinoma showing rapid progression of peritoneal dissemination after immune checkpoint inhibitor therapy

AU - Shinozaki, Taro

AU - Iwami, Eri

AU - Ikemura, Shinnosuke

AU - Matsuzaki, Tatsu

AU - Nakajima, Takahiro

AU - Hashimoto, Kazuhiko

AU - Terashima, Takeshi

PY - 2018/5/31

Y1 - 2018/5/31

N2 - Background: Immune checkpoint inhibitors are standard treatments for non-small cell lung cancer. Unique cases with paradoxical acceleration of the disease after immunotherapy have been reported. These have been described as cases of hyperprogressive disease. Case presentation: A 76-year-old man was diagnosed with pulmonary adenocarcinoma with pleural dissemination and liver and adrenal metastases. Genomic analysis revealed neither EGFR mutations nor ALK translocations. Immunohistochemical analysis revealed a programmed death-ligand 1 tumor proportion score of 23%. Chemotherapy with carboplatin, paclitaxel, and bevacizumab resulted in Grade 3 skin eruption and disease progression. Pembrolizumab was initiated as a second-line treatment. However, peritoneal dissemination and ascites developed. The patient died 2weeks later. The autopsy revealed widespread peritoneal dissemination and an extensive hemorrhagic infarction. Conclusion: This was a rare case of hyperprogressive disease with rapid progression of peritoneal dissemination after pembrolizumab treatment.

AB - Background: Immune checkpoint inhibitors are standard treatments for non-small cell lung cancer. Unique cases with paradoxical acceleration of the disease after immunotherapy have been reported. These have been described as cases of hyperprogressive disease. Case presentation: A 76-year-old man was diagnosed with pulmonary adenocarcinoma with pleural dissemination and liver and adrenal metastases. Genomic analysis revealed neither EGFR mutations nor ALK translocations. Immunohistochemical analysis revealed a programmed death-ligand 1 tumor proportion score of 23%. Chemotherapy with carboplatin, paclitaxel, and bevacizumab resulted in Grade 3 skin eruption and disease progression. Pembrolizumab was initiated as a second-line treatment. However, peritoneal dissemination and ascites developed. The patient died 2weeks later. The autopsy revealed widespread peritoneal dissemination and an extensive hemorrhagic infarction. Conclusion: This was a rare case of hyperprogressive disease with rapid progression of peritoneal dissemination after pembrolizumab treatment.

KW - Adenocarcinoma

KW - Hyperprogressive disease

KW - Immune checkpoint inhibitor

KW - Lung cancer

KW - Pembrolizumab

KW - Peritoneal dissemination

UR - http://www.scopus.com/inward/record.url?scp=85047913347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047913347&partnerID=8YFLogxK

U2 - 10.1186/s12885-018-4549-5

DO - 10.1186/s12885-018-4549-5

M3 - Article

C2 - 29855288

AN - SCOPUS:85047913347

VL - 18

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 620

ER -